- $1.32bn
- $1.48bn
- $660.57m
- 82
- 53
- 47
- 64
Annual income statement for Neogenomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 444 | 484 | 510 | 592 | 661 |
| Cost of Revenue | |||||
| Gross Profit | 186 | 187 | 188 | 245 | 290 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 460 | 603 | 667 | 699 | 753 |
| Operating Profit | -15.4 | -119 | -158 | -108 | -92.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.1 | -15.1 | -159 | -97.1 | -80.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 4.17 | -8.35 | -144 | -88 | -78.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 4.17 | -8.35 | -144 | -88 | -78.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 4.17 | -8.35 | -144 | -88 | -78.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.014 | 0.083 | -1.08 | -0.632 | -0.487 |